Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995–2001  by Rimbara, E. et al.
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01099.x
Susceptibilities to clarithromycin, amoxycillin and metronidazole of
Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan,
1995–2001
E. Rimbara1, N. Noguchi1, M. Tanabe1, T. Kawai2, Y. Matsumoto3 and M. Sasatsu1
1Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Science,
2Endoscopy Center, Tokyo Medical University and 3Hachioji Pharmaceutical Center Pharmacy,
Hachioji, Tokyo, Japan
ABSTRACT
The aim of this study was to determine the susceptibilities to clarithromycin, amoxycillin and
metronidazole of Helicobacter pylori isolates from the antrum and corpus of Japanese patients examined
during the period 1995–2001. There was an increase, from 6.2% in 1995 to 22.1% in 2000–2001, in the
proportion of patients infected with clarithromycin-resistant H. pylori. Of patients infected with
clarithromycin-resistant H. pylori, 39.1% were infected with both clarithromycin-susceptible and
-resistant H. pylori. Furthermore, the MIC90 of clarithromycin for H. pylori rose from <1 mg ⁄L in 1995–
1998 to 8 mg ⁄L in 1999. In contrast, the MIC90s of amoxycillin and metronidazole were £ 0.125 and
4 mg ⁄L, respectively, throughout the study period. The results showed that, while most H. pylori isolates
were susceptible to amoxycillin and metronidazole, resistance to clarithromycin among H. pylori isolates
increased markedly in Japan during 1995–2001. The results also indicated a need to test the susceptibility
of H. pylori isolates from more than two samples obtained from two different sites in the stomach of a
single patient in order to diagnose the presence of clarithromycin-resistant H. pylori correctly.
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INTRODUCTION
Helicobacter pylori causes peptic ulcer and chronic
gastritis [1,2], and has also been associated with
gastric cancer and mucosal-associated lymphoid
tissue lymphoma [3,4]. In Japan, H. pylori is
usually eradicated by a triple therapy which
includes amoxycillin, clarithromycin and a proton
pump inhibitor [5]. Although this treatment is
successful in 70–90% of cases [5–7], treatment
failure can result from the presence of antimicro-
bial-resistant strains of H. pylori [8–10]. In such
cases, clarithromycin is usually replaced by met-
ronidazole [5,11]. However, infection with resist-
ant strains of H. pylori results in a decreased
eradication rate compared to that obtained with
susceptible strains [12–14]. In addition, mixed
infections with H. pylori strains of different anti-
bacterial susceptibilities have been reported
[15–17]. For these reasons, information regarding
the prevalence of antimicrobial-resistant H. pylori
strains is important in predicting the therapeutic
response. The present study investigated the
susceptibilities to clarithromycin, amoxycillin
and metronidazole of H. pylori isolates from
gastric biopsies taken from two sites, the antrum
and corpus, during the period 1995–2001.
MATERIALS AND METHODS
Patients
H. pylori isolates were obtained from 692 Japanese patients (469
male and 223 female; mean age 51.0 ± 12.1 years, range
12–77 years) who underwent upper endoscopy for evaluation
of symptoms related to the upper gastrointestinal tract at
Tokyo Medical University Hachioji Medical Center, or at
Tokyo Medical University Hospital, Tokyo, Japan, between
1995 and 2001. The diagnoses included chronic gastritis, peptic
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ulcer, mucosal-associated lymphoid tissue lymphoma, gastric
polyps and gastric cancer. The samples were taken before the
use of any eradication therapy. H. pylori infection was
diagnosed by culture of gastric biopsy specimens obtained
from the antrum and corpus. Informed consent was obtained
from all patients.
Culture
H. pylori was cultured from gastric biopsy specimens on
modiﬁed Skirrow agar (Nissui Pharmaceutical Co., Tokyo,
Japan) under microaerophilic conditions (O2 5%, CO2 10%, N2
85%) for 3–7 days at 37C. H. pylori was identiﬁed by oxidase
production and API Campy tests (bioMe´rieux, Marcy l’Etoile,
France). Isolates were stored in Microbank vials (Pro-Laborat-
ory Diagnostics, Richmond Hill, Ontario, Canada) or brain–
heart infusion broth containing glycerol 20% v ⁄v, either at
) 80C or at ) 198C in liquid nitrogen.
Susceptibility testing
The susceptibilities of H. pylori isolates to clarithromycin,
amoxycillin and metronidazole were tested by the NCCLS agar
dilutionmethod [18]. Brieﬂy,H. pylori isolateswere subcultured
for 3 days as described above, followed by the preparation of a
2 · McFarland standard in sterile saline. Aliquots (5 lL) of the
suspension were then spotted on to Mueller–Hinton agar
containing horse blood 5% v ⁄v. MICs were determined after
incubation for 3 days.H. pylori isolateswere deﬁned as resistant
when the MICs of clarithromycin, amoxycillin andmetronidaz-
ole were ‡ 1, ‡ 1 and ‡ 16 mg ⁄L, respectively. H. pylori strain
ATCC 43504 was used as a quality control organism.
Statistical analysis
Differences in the annual proportions of patients infected with
antimicrobial-resistant H. pylori were tested by the v2 test, with
p < 0.05 considered to be statistically signiﬁcant.
RESULTS
Incidence of patients with infection by
antibacterial-resistant strains
Table 1 shows the overall proportion of patients
from whom antimicrobial-resistant H. pylori iso-
lates were obtained, as well as the source of the
isolates. The patients were divided into three
groups: (1) Ra ⁄ Sb group, containing patients with
antimicrobial-resistant H. pylori isolates from the
antrum and antimicrobial-susceptible H. pylori
isolates from the corpus; (2) Sa ⁄Rb group, con-
taining patients with antimicrobial-susceptible
isolates from the antrum and antimicrobial-resist-
ant isolates from the corpus; and (3) Ra ⁄Rb group,
containing patients with antimicrobial-resistant
isolates from both antrum and corpus.
Regardless of the above groups, the proportion
of patients with clarithromycin-resistant H. pylori
isolates was higher than the proportion of
patients with amoxycillin- or metronidazole-
resistant isolates. The patients with clarithromy-
cin-resistant H. pylori isolates included 7.2% (39)
of patients in the Ra ⁄Rb group, compared with
1.8% (ten) patients in the Ra ⁄ Sb group, and 2.8%
(15) patients in the Sa ⁄Rb group. Thus, in total,
39.1% (25 ⁄ 64) of the patients with clarithromycin-
resistant isolates were infected with both
clarithromycin-resistant and -susceptible H. pylori
isolates. Similarly, two of three patients with
amoxycillin-resistant H. pylori isolates, and four
of eight patients with metronidazole-resistant
H. pylori isolates, yielded both resistant and
susceptible isolates.
Annual proportion of patients with
antimicrobial-resistant H. pylori
The annual proportions of patients from whom
antimicrobial-resistant H. pylori strains were iso-
lated, from the antrum and ⁄ or the corpus, are
shown in Table 2. The annual proportion of
patients infected with isolates resistant to amoxy-
cillin or metronidazole was < 5% during 1995–
2001. In contrast, the proportion of patients
infected with clarithromycin-resistant H. pylori
Table 1. Proportions of patients infected with antimicro-
bial-resistant Helicobacter pylori according to the site of
isolation (antrum and ⁄ or corpus)
Antimicrobial agent
% resistance rate (number of patients)
Ra/Sb Sa/Rb Ra/Rb
Clarithromycin 1.8 (10 ⁄ 542) 2.8 (15 ⁄ 542) 7.2 (39 ⁄ 542)
Amoxycillin 0.4 (2 ⁄ 546) 0.0 (0 ⁄ 546) 0.2 (1 ⁄ 546)
Metronidazole 0.2 (1 ⁄ 541) 0.6 (3 ⁄ 541) 0.7 (4 ⁄ 541)
S, sensitive; R, resistant.
Ra ⁄ Sb group, patients with antimicrobial-resistant H. pylori isolates from the
antrum and antimicrobial-susceptible H. pylori isolates from the corpus; Sa ⁄Rb
group, patients with antimicrobial-susceptible isolates from the antrum and
antimicrobial-resistant isolates from the corpus; Ra ⁄Rb group, patients with
antimicrobial-resistant isolates from both antrum and corpus.
Table 2. Annual variation in the number of patients from
whom antimicrobial-resistant Helicobacter pylori strains
were isolated
Year
Number (%) of patients with H. pylori resistant to
Clarithromycin Amoxycillin Metronidazole
1995 10 ⁄ 162 (6.2) 1 ⁄ 161 (0.6) 1 ⁄ 162 (0.6)
1996 10 ⁄ 143 (7.0) 1 ⁄ 144 (0.7) 2 ⁄ 144 (1.4)
1997 7 ⁄ 90 (7.8) 0 ⁄ 90 (0.0) 0 ⁄ 90 (0.0)
1998 7 ⁄ 65 (10.8) 1 ⁄ 65 (1.5) 1 ⁄ 65 (1.5)
1999 28 ⁄ 163 (17.2) 0 ⁄ 163 (0.0) 7 ⁄ 163 (4.3)
2000–2001 15 ⁄ 68 (22.1) 0 ⁄ 68 (0.0) 0 ⁄ 66 (0.0)
Total 77 ⁄ 691 (11.1) 3 ⁄ 691 (0.4) 11 ⁄ 690 (1.6)
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rose signiﬁcantly (p < 0.05) from 6.2% (95% CI,
3.4–11.0) in 1995 to 22.1% (95% CI, 13.8–33.3) in
2000–2001.
Annual variation in MIC90
Fig. 1 shows the annual variation in MIC90s of
clarithromycin, amoxycillin, and metronidazole.
Although the MIC90 of clarithromycin for H. pylori
isolates during 1995–1998 was < 1 mg ⁄L, the
MIC90 in 1999 increased to 8 mg ⁄L, which exceed-
ed the recommended breakpoint of 1 mg ⁄L. In
contrast, the MIC90s of amoxycillin and metroni-
dazole were < 0.125 and 4 mg ⁄L, respectively,
throughout the entire period of the study every
year. The MIC50s of clarithromycin, amoxycillin
and metronidazole were lower than the level of
resistance.
Multiresistant H. pylori
Multiresistant isolates of H. pylori, i.e., resistant to
more than two antimicrobial agents, including
clarithromycin, were obtained from three pa-
tients, with two of these patients being infected
with both clarithromycin- and amoxycillin-resist-
ant H. pylori (clarithromycin and amoxycillin
MICs of 32 and 1 mg ⁄L, and 16 and 1 mg ⁄L,
respectively). The remaining patients yielded
H. pylori isolates with clarithromycin and metro-
nidazole MICs of 32 and 64 mg ⁄L, respectively.
Among patients with clarithromycin-resistant
H. pylori, the proportion infected with multire-
sistant H. pylori was 3.9% (3 ⁄ 77).
DISCUSSION
This study investigated the susceptibilities of
H. pylori isolates from the antrum and corpus to
various antimicrobial agents, and the proportion
of patients infected with resistant H. pylori, during
the period 1995–2001. Among the patients with
clarithromycin-resistant H. pylori, 39% yielded
both clarithromycin-resistant and clarithromycin-
susceptible H. pylori isolates. Kim et al. [16]
reported the possibility that genomic alterations
in pre-existing strains result in the simultaneous
presence of antimicrobial-susceptible and -resist-
ant strains in the same patient. Although no
genotypic analysis was performed, it is possible
that this explanation could account for the
observations in the present study. Furthermore,
Kawai et al. [19] reported that mixed infection by
clarithromycin-susceptible and -resistant H. pylori
strains could prevent eradication of H. pylori by
the triple therapy and result in the selection of the
resistant strains. Therefore, the present results
emphasise the need to test the susceptibility of
bacteria isolated from both the gastric antrum and
corpus of the same patient in order to diagnose
clarithromycin-resistant H. pylori infection cor-
rectly.
Year
M
IC
90
(m
g/
L)
M
IC
90
(m
g/
L)
M
IC
90
(m
g/
L)
(a)
(b)
(c)
1995 1996 1999 2000–200119981997
1995 1996 1999 2000–200119981997
1995 1996 1999 2000–200119981997
64
4
8
16
32
0.063
0.125
0.25
0.5
1
2
0.016
0.031
0.008
64
4
8
16
32
0.063
0.125
0.25
0.5
1
2
0.016
0.031
0.008
64
4
8
16
32
0.063
0.125
0.25
0.5
1
2
0.016
0.031
0.008
Fig. 1. Annual variation in MIC90s of (a) clarithromycin,
(b) amoxycillin and (c) metronidazole for Helicobacter pylori
isolates between 1995 and 2001. Squares, H. pylori isolates
from the antrum; triangles, H. pylori isolates from the
corpus.
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The data indicated that the proportion of
patients with clarithromycin-resistant H. pylori
has increased markedly in Japan, especially when
compared to the proportion of patients with
amoxycillin- and metronidazole-resistant H. py-
lori. Previous studies in Japan [20,21] have also
reported an increase in clarithromycin-resistant
H. pylori in recent years. Clarithromycin resist-
ance in H. pylori has been associated with point
mutations in domain V of the 23S rRNA gene,
which is the binding site of macrolides, including
clarithromycin [22–24]. Macrolides are used
widely for the treatment of infections caused by
Mycoplasma spp. [25] and Gram-positive bacteria
[26], and are also used currently in Japan for the
treatment of diffuse panbronchiolitis caused by
Pseudomonas aeruginosa [27]. It has been reported
in Japan since 1998 that eradication therapy
involving clarithromycin is a safe and effective
regimen [7]. As a result, clinical use of macrolides,
including clarithromycin, has increased signiﬁ-
cantly in recent years. The signiﬁcant increase in
the MIC90 of clarithromycin for H. pylori between
1998 and 1999 is therefore probably associated
with the increased use of clarithromycin in Japan.
The total proportion of metronidazole-resistant
H. pylori isolates in the present study was 1.6%,
which is lower than the proportions of 12.4% and
9% reported by Kato et al. [21] and Perez et al. [20],
respectively. However, Kato et al. [21] also showed
the presence of regional differences in the propor-
tions of metronidazole-resistant isolates in Japan,
and these regional differences might also account
for the relatively low proportion of metronidazole-
resistant H. pylori isolates in the present study.
Multiresistant H. pylori isolates were also
observed in the present study, and all such
multiresistant H. pylori isolates were resistant to
clarithromycin. Since the frequency of amoxycil-
lin- and metronidazole-resistant H. pylori was far
lower than that of clarithromycin-resistant
H. pylori, it seems likely that multiresistance
results from the acquisition of amoxycillin
and metronidazole resistance by clarithromycin-
resistant H. pylori isolates.
In conclusion, the present study demonstrated
an increased frequency of clarithromycin-resist-
ant H. pylori isolates and the presence of multi-
resistant H. pylori isolates in Japan. These results
suggest a need to develop alternatives to the
clarithromycin-containing eradication therapy
used currently.
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